A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Overview

REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling. In this way, it increases hepatic glucose uptake, decreases hepatic glycogenolysis and gluconeogenesis, increases glycogen synthesis, and ultimately decreases blood glucose levels. This protocol will test the hypotheses that REMD-477 is safe and tolerable in patients with severe hyperglycemia on copanlisib and that it decreases the risk of severe hyperglycemia in patients receiving copanlisib for relapsed refractory lymphoma

Full Title of Study: “A Phase I/Ib Pilot Study to Determine the Safety and Efficacy of a Human Anti-glucagon Receptor Antibody (REMD-477) in Controlling Severe Hyperglycemia Due to Copanlisib in Patients With Relapsed or Refractory Lymphoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 5, 2021

Interventions

  • Biological: REMD-477
    • REMD-477 will be administered as a subcutaneous injection for three weekly doses

Arms, Groups and Cohorts

  • Experimental: REMD-477
    • REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses

Clinical Trial Outcome Measures

Primary Measures

  • Adverse Events
    • Time Frame: 22 days
    • Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase inhibitor
  • Serious Adverse Events
    • Time Frame: 22 days
    • Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase
  • Liver Function Tests (LFT) units per liter (u/L)
    • Time Frame: 22 days
    • Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase
  • Blood Glucose measurements
    • Time Frame: 22 days
    • Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase
  • Pulse beats per minute
    • Time Frame: 22 days
    • Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase
  • breathing Rate breaths per minute
    • Time Frame: 22 days
    • Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase

Secondary Measures

  • Fasting Glucose levels
    • Time Frame: 22 days
    • Determine efficacy of REMD-477 in preventing copanlisib induced hyperglycemia
  • Insulin levels
    • Time Frame: 22 days
    • Determine efficacy of REMD-477 in preventing copanlisib induced hyperglycemia

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18 or older – Relapsed or refractory lymphoma (Grade 1, 2, 3A) – Received 2 or more prior lines of systemic therapy for lymphoma – Experienced glucose >250 mg/dL after copanlisib infusion for treatment of lymphoma Exclusion Criteria:

  • Evidence of histologic transformation – Follicular Lymphoma Grade 3B – Active CNS involvement by malignancy – Elevated AST or ALT > 5x ULN at Screening – Unmanageable sensitivity to mammalian-derived drug preparations, or to humanized or human antibodies; managed sensitivities to agents such as obinutuzumab or rituximab or similar agents are not exclusionary – History of drug or alcohol abuse within the last 6 months – History or family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia – History or family history of pheochromocytoma – Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness) conditions specific to diabetes that would pose additional risk to subject's safety or interfere with the study evaluation, procedures or completion in the opinion of the treating physician. – Female subject is pregnant or breastfeeding.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Duke University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Herbert Lyerly, Professor – Duke University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.